Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Steve Abbott

Steve Abbott was diagnosed with prostate cancer four years ago, at age 50. Following a radical prostatectomy in September 2013, Steve experienced a biochemical recurrence in spring of 2014.

In March of that same year Steve began a series of 33 radiation treatments, but his PSA still began to rapidly increase. It was at the conclusion of these treatments that he also became a caregiver to his wife, who’d just been diagnosed with an invasive form of breast cancer.

By November 2016, Steve’s PSA was 22, and he began hormone therapy just a month later. Now Steve continues to treat his disease while mentoring newly diagnosed men as they navigate their prostate cancer journeys.

It is not lost on me that I have enough open road in front of me to hopefully make it to the next great treatment as a result of the groundbreaking work that has been done in the last 20 to 25 years, facilitated by organizations like ZERO. Others made those advances to help me and I hope to do what I can to pass the baton.

In addition to being a mentor, Steve is also a recognized speaker on cancer survivorship. He and his wife are tireless advocates for the importance of cancer awareness, early detection, research, and support for survivors. This year, they attended the ZERO Annual Summit in Washington, D.C. to speak with their elected officials about protecting prostate cancer research funding.

I have such respect for ZERO and its mission. Thanks to ZERO for all that they do to advance the quality of prostate cancer care and research.